Newsbenzinga
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition
· Published
Article summary
Shares of Tempus AI are surging Wednesday morning as traders connected the dots between a landmark clinical trial win and Tempus’s recent multi-billion dollar acquisition deal.
An excerpt from the original article.
Comments —
Loading comments…